Seval Ozkan

Seval Ozkan

Auto-generated profile, based on publicly available information

Seval Ozkan

Cancer Institute, University of Mississippi Medical Centre 2 , Jackson, MS, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2019 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
PPParash Parajuli
Parash Parajuli
PSPurba Singh
Purba Singh
ZWZhe Wang
Zhe Wang
LLLianna Li
Lianna Li
SESailaja Eragamreddi
Sailaja Eragamreddi
AAAzeddine Atfi
Azeddine Atfi
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

24 February 2023 in Journal of Cell Biology
Verified
Journal Article
Open access
PDF file
EHEric Hurwitz
Eric Hurwitz
PPParash Parajuli
Parash Parajuli
SOSeval Ozkan
Seval Ozkan
CPCeline Prunier
Celine Prunier
TNThien Ly Nguyen
Thien Ly Nguyen
AAAzeddine Atfi
Azeddine Atfi
The transcription factor Prdm16 functions as a potent suppressor of transforming growth factor-beta (TGF-β) signaling, whose inactivation is deemed essential to the progression of pancreatic ductal adenocarcinoma (PDAC). Using the KrasG12D-based mouse model of human PDAC, we surprisingly found that ablating Prdm16 did not block but instead accelerated PDAC formation and progression, suggesting that Prdm16 might function as a tumor suppressor in this malignancy. Subsequent genetic experiments showed that ablating Prdm16 along with Smad4 resulted in a shift from a well-differentiated and confined neoplasm to a highly aggressive and metastatic disease, which was associated with a striking deviation in the trajectory of the premalignant lesions. Mechanistically, we found that Smad4 interacted with and recruited Prdm16 to repress its own expression, therefore pinpointing a model in which Prdm16 functions downstream of Smad4 to constrain the PDAC malignant phenotype. Collectively, these findings unveil an unprecedented antagonistic interaction between the tumor suppressors Smad4 and Prdm16 that functions to restrict PDAC progression and metastasis.